As per drug sales record of 2016, eight out of ten top-selling drugs are biologics. Upcoming patent expiry of biologics is leading to increased R&D for biosimilar formulations. Biopharma players in the market are adopting price reduction strategies in order to promote their products. This is triggering the need for consideration of pricing strategy among excipient manufacturers.
Presence of challenges in development of a stable form of biotherapeutic is urging manufacturers to develop novel excipients. Processing and storage of biomolecules are complicated as these products undergo degradation after a slight change in environmental conditions. Rising demand for chemicals that are compatible with these biomolecules and serve additional functions such as binding, bulking, and efficient delivery is stimulating the growth of the market. Technological advancements, such as implementation of nanotechnology in the development of novel compounds to enhance drug delivery, are likely to drive the market. For instance, an Australian provider of microencapsulation for drug delivery, Ceramisphere, expanded its operations for production of nanoparticles with extended-release capacity.
Furthermore, Asian countries such as India & China serve as major markets for biogenerics. Key pharmaceutical players in the market are increasing their R&D activities on follow-on-biologic. Biologics R&D is outsourced to CROs in the region as a consequence of cost efficiency provided by them, which is consequently boosting the demand for excipients.
Asia Pacific Biopharma Excipients Market Report Highlights
- Carbohydrates accounted the largest revenue share due to substantial product penetration in the market owing to higher availability of raw materials as well as easy molecular processing characteristics
- Japan dominated the market in terms of revenue. However, in terms of sale volume, the Japanese economy was not on the top as a consequence of high product pricing
- In February 2014, International Pharmaceutical Excipients Council of India (IPEC) was launched. Leading international pharmaceutical companies are founder members of this council, which includes Dow Chemicals, Lubrizol, BASF, SPI Pharma, Colorcon, Indchem International. It is estimated to assist the government of India in evolving direction, standards, and development of the excipient industry in the country, thus working in favor of the market
- In August 2016, China FDA announced to review excipients as a part of new drug application. The former system considered separate review approvals for a drug, its excipient, and its active ingredient.
The leading players in the Asia Pacific Biopharma Excipients market include:
- Signet Excipients Pvt. Ltd.
- ABITEC
- Sigachi Industries.
- Roquette Frères
- Colorcon
- Meggle GmbH & Co. KG
- CLARIANT
- DFE Pharma
- SPI Pharma
- IMCD.
- Spectrum Chemical
- Pharmonix
- BASF SE
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
The leading players in the Asia Pacific Biopharma Excipients market include:- Signet Excipients Pvt. Ltd.
- ABITEC
- Sigachi Industries.
- Roquette Frères
- Colorcon
- Meggle GmbH & Co. KG
- CLARIANT
- DFE Pharma
- SPI Pharma
- IMCD.
- Spectrum Chemical
- Pharmonix
- BASF SE
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 100 |
Published | September 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 761.2 Million |
Forecasted Market Value ( USD | $ 1100 Million |
Compound Annual Growth Rate | 5.8% |
Regions Covered | Asia Pacific |
No. of Companies Mentioned | 14 |